

CancerPACT™



Cancer Patients Alliance for Clinical Trials

Greater PHOENIX Area

Adult Cancer Clinical Trials

Winter 2011

Solid Tumors

1. Breast	2
2. Central Nervous System	4
3. Gastrointestinal	5
4. Gynecologic	7
5. Head and Neck	8
6. Lung	9
7. Melanoma / Skin.....	10
8. Prostate	11
9. Urologic	12
10. Endocrine	13
11. Sarcoma	13

Hematologic Cancers

1. Leukemia	14
2. Lymphoma	15
3. Myeloma	16

Phase I Studies

Other

Phoenix Area Clinical Trials Centers

Arizona Breast Cancer Specialists (ABCS): 480-922-4600, Arizona Cancer Center (ACC): 480-860-5000
Arizona Oncology Services Foundation (AOS): 602-274-4484, Arizona Oncology (AO) -
<http://www.arizonaoncology.com/>, Bladder Cancer Genitourinary Oncology (BCGO): 602-493-6626
Eli Lilly (LILLY): 877-285-4559, Genentech (GENE): 888-662-6728, GSK Investigational Site, Scottsdale
(GSK): 800-379-3718, Harbor BioSciences, Inc., Scottsdale (HARBOR): 858-320-2591, ImClone
Investigational Site, Scottsdale (IMCLONE): [clinicaltrials@ ImClone.com](mailto:clinicaltrials@ImClone.com), Ironwood Cancer & Research
Centers, Chandler (IRONWOOD): 480-821-2838, Mayo Clinic (MAYO): 480-301-8000, Merck & Company
(MERCK): 888-577-8839, Pivotal Research Centers (PIVOTAL): 623-977-1234, Premiere Oncology of Arizona
(PREMIERE): 480-860-5000, Translational Genomics Research Institute (TGEN): 866-370-8436, Scottsdale
Healthcare (SH): 480-882-4000, St. Joseph's Hospital & Medical Center (ST. JOSEPH): 602-406-3000

**CancerPACT is an initiative of Cancer Patients Alliance in Partnership
with Phoenix based Arizona Bridge to Independent Living**

Call (toll free) 1-888-729-0244

www.CancerPACT.org

Solid Tumors

1. Breast Cancer

1. 10-0204-10, CALGB 40601 Phase III Randomized Trial of Paclitaxel Combined with Trastuzumab, Lapatinib, or both as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer (ACC)
2. **20765 Phase III Randomized Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-Expressing Metastatic Breast Cancer (ACC)**
3. 20766 Phase III Double-Blind Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer (ACC)
4. **112525 Phase III Trial of Continued HER2 Suppression with Lapatinib plus Trastuzumab vs. Trastuzumab Alone (GSK)**
5. 20091758 Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Daily Everolimus in Combination with Trastuzumab and Vinorelbine, in Pretreated Women with HER2/Neu Over-Expressing Locally Advanced or Metastatic Breast Cancer (ACC)
6. **20100167 Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE) (ACC)**
7. CALB-40502 Phase III Study using Bevacizumab and Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone in Treating Patients with Stage IIIC or Stage IV Breast Cancer (MAYO)
8. **CRAD001J2301 Phase III Everolimus in Combination with Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (IRONWOOD)**
9. CRAD001Y2391 Phase III Trial using Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are Refractory to Letrozole or Anastrozole (IRONWOOD, PREMIERE)
10. **ECOG-E5103 Phase III Trial using Doxorubicin, Cyclophosphamide, and Paclitaxel with or without Bevacizumab in Treating Patients with Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (MAYO)**
11. N063D/BIG 2-06, ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study - Phase III Randomized, Multi-Centre, Open-Label Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/Erbb2 Positive Primary Breast Cancer (GSK, MAYO)
12. **NSABP-B-39 Phase III Radiation Therapy in Treating Women who have Undergone Surgery for Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer (ABCS, AOS, MAYO, PREMIER)**
13. NSABP B-46-I Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (AO)
14. **S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer (ACC)**
15. TDM4370g Phase III Open-Label Study of Trastuzumab-MCC-DM1 (T-DM1) vs. Capecitabine + Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (IRONWOOD)
16. **Z1031 Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant (Given Before Surgery) Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Stage II and III Estrogen Receptor Positive Breast Cancer (MAYO)**

17. Phase III Trial of Combination Chemotherapy Followed by Docetaxel or Ixabepilone in Treating Patients who have Undergone Surgery for Nonmetastatic Breast Cancer (MAYO)
- 18. 07-0327-04 Phase II Study Irinotecan and Etoposide as Treatment for Refractory, Metastatic Breast Cancer (ACC)**
19. 08007 Phase II Trial Ixabepilone + Carboplatin Metastatic Breast Cancer (PREMIER)
- 20. CHNMC-PHII-96 Phase II Trial Evaluating Veliparib with or without Carboplatin in Treating Patients with Stage III or Stage IV Breast Cancer (MAYO)**
21. NCCTG-N0733 Phase II Trial using Capecitabine and Lapatinib with or without Cixutumumab in Treating Patients with Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer (MAYO)
- 22. NCCTG-N0937 Phase II Trial using Brostallicin and Cisplatin in Treating Patients with Metastatic Breast Cancer (MAYO)**
23. NCCTG-N1031 Phase II Trial of Pixantrone Dimaleate in Treating Patients with HER2-Negative Metastatic Breast Cancer (MAYO)
- 24. Phase II Trial of Lapatinib and Trastuzumab with or without Endocrine Therapy in Locally Advanced HER2 Overexpressing Breast Cancer Patients (MAYO)**
25. NCCTG-N093B Phase II/I Trial Evaluating Panobinostat and Letrozole in Treating Patients with Metastatic Breast Cancer (MAYO)
- 26. HERQLES Phase IB Single-Arm, Open-Label Clinical Trial to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients with Her2-Positive Metastatic or Locally Advanced Inoperable Cancer (ACC)**
27. 10-0884-04 Phase I Trial of Weekly Paclitaxel in Combination with Bavituximab in Patients with Her-2 Negative Metastatic Breast Cancer (ACC)
- 28. MM-121-04-01-04 Phase I Pharmacologic and Pharmacodynamic Study of MM-121 in Combination with Paclitaxel in Patients with Advanced Gynecologic and Breast Cancers (ACC, PREMIER)**
29. 10-0214-04 Prospective Lymphedema Surveillance in Patients with Invasive Breast Cancer Scheduled for Axillary Radiation (ACC)
- 30. 20081765 Open-Label Study of AMG 386 in Combination with Either Paclitaxel or Trastuzumab or Capecitabine and Lapatinib in Subjects with Her2-positive Locally Recurrent or Metastatic Breast Cancer (ACC)**
31. 20091608 Randomized Double-Blind Placebo-Controlled Trial of Neratinib (HKI-272) after Trastuzumab in Women with Early-Stage HER-2/Neu Overexpressed/Amplified Breast Cancer (ACC, AO)
- 32. 20101430 A Two Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients (ACC)**
33. CRAD001Y2301 Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole (ACC)
- 34. Bicalutamide in Treating Patients with Metastatic Breast Cancer (MAYO)**
35. Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation with or without Vorinostat in Treating Women with Breast Cancer that can be Removed by Surgery (MAYO)
- 36. Cixutumumab and Tlemsirrolimus in Treating Patients with Locally Recurrent or Metastatic Breast Cancer (MAYO)**
37. Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women with Palpable Breast Cancer that can be Removed by Surgery (MAYO)
- 38. Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women with Breast Cancer (MAYO)**
39. Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women who are Undergoing Surgery for Stage II or Stage III Breast Cancer (MAYO)

**CancerPACT is an initiative of Cancer Patients Alliance in Partnership
with Phoenix based Arizona Bridge to Independent Living**

Call (toll free) 1-888-729-0244
www.CancerPACT.org

- 40. I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (MAYO)**
- 41. Lapatinib in Combination with Trastuzumab in Patients with HER2-Positive, Metastatic Breast Cancer (MAYO)
- 42. Lapatinib in Treating Women with Ductal Carcinoma In Situ of the Breast (MAYO)**
- 43. Pixantrone Dimaleate in Treating Patients with HER2-Negative Metastatic Breast Cancer (MAYO)
- 44. Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes after Chemotherapy in Treating Women with Stage II, Stage IIIA, or Stage IIIB Breast Cancer (MAYO)**
- 45. Tamoxifen in Women with Breast Cancer and in Women at High-Risk of Breast Cancer who are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline (MAYO)
- 46. Triptorelin with Either Exemestane or Tamoxifen in Treating Premenopausal Women with Hormone-Responsive Breast Cancer (MAYO)**

2. Central Nervous System Tumors

- 1. ECOG-E3F05 Phase III Trial of Radiation Therapy with or without Temozolomide in Treating Patients with Low-Grade Glioma (AOS, MAYO)
- 2. NCCTG-N0574 Phase III Trial using Stereotactic Radiation Therapy with or without Whole-Brain Radiation Therapy in Treating Patients with Brain Metastases (AOS, MAYO)**
- 3. 09-0911-04, RTOG 0627 Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme (ACC)
- 4. NCCTG-N0577 Phase III Trial using Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide alone in Treating Patients with Newly Diagnosed Anaplastic Glioma (MAYO)**
- 5. RTOG-0825 Phase III Trial using Temozolomide and Radiation Therapy with or without Bevacizumab in Treating Patients with Newly Diagnosed Glioblastoma (AOS)
- 6. RTOG-0837 Phase II Study of Temozolomide and Radiation Therapy with or without Cediranib Maleate in Treating Patients with Newly Diagnosed Glioblastoma (AOS)**
- 7. 10-0211-04 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate and High Risk Meningiomas (ACC)
- 8. EMD 121974-009 Phase II Trial using Cilengitide (WMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) (ST. JOSEPH)**
- 9. RTOG-0539 Phase II Trial using Observation or Radiation Therapy in Treating Patients with Grade I, Grade II, or Grade III Meningioma (AOS)
- 10. NCCTG-N057K Phase II/I Trial using Everolimus, Temozolomide, and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma (MAYO)**
- 11. Dasatinib and Bevacizumab in Treating Patients with Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme (MAYO)
- 12. Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma Multiforme (MAYO)**
- 13. Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients with Newly Diagnosed High- or Low-Grade Malignant Glioma (MAYO)
- 14. Imatinib Mesylate in Treating Patients with Recurrent Brain Tumor (MAYO)**
- 15. Sorafenib and Temozolomide in Treating Patients with Recurrent Glioblastoma (MAYO)
- 16. Viral Therapy in Treating Patients with Recurrent Glioblastoma Multiforme (MAYO)**

3. Gastrointestinal Cancers

A. Colorectal Cancer

1. CALB-08702 Phase III Trial using Oxaliplatin, Leucovorin Calcium, and Fluorouracil with or without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated with Surgery (MAYO)
2. **E5202 Phase III Study Comparing 5-FU (5-fluorouracil) Leucovorin and Oxaliplatin vs. 5-FU, Leucovorin, Oxaliplatin and Bevacizumab (Avastin) in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (MAYO)**
3. 10-0006-04, S0713 Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-Operative Therapy Of Rectal Cancer (ACC)
4. **20090468 Phase II Study of EZN-2208 (PEG-SN38) Administered with or without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC) (ACC)**
5. MAYO-MC084B Phase II Trial using Azacitidine and Entinostat in Treating Patients with Metastatic Colorectal Cancer (MAYO)
6. **CA206-001 Phase I/II Study of BMS-908662 (XL281) Alone or in Combination with Cetuximab in Subjects with K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer (ACC, PREMIER)**
7. Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients with Metastatic or Unresectable Locally Advanced Small Bowel Cancer (MAYO)
8. **Laparoscopic-Assisted Resection or Open Resection in Treating Patients with Stage IIA, Stage IIIA or Stage IIIB Rectal Cancer (MAYO)**

B. Esophageal Cancer

1. NCCTG-N0849 Phase II Trial of Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients with Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction (MAYO)
2. **Capecitabine with or without Sunitinib Malate as First-Line Therapy in Treating Patients with Metastatic Cancer of the Esophagus or Gastroesophageal Junction (MAYO)**
3. Esomeprazole with or without Aspirin in Preventing Esophageal Cancer in Patients with Barrett Esophagus (MAYO)
4. **Paclitaxel with or without Cixutumumab as Second-Line Therapy in Treating Patients with Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (MAYO)**

C. Liver Cancer

1. ECOG-E1208 Phase III Study of Mapatumumab in Combination with Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (MAYO)
2. **Phase III Study of ThermoDox with Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) (MAYO)**
3. 13931 Phase II Study of IMC-A12 in Combination with Sorafenib in Patients with Advanced Cancer of the Liver (IMCLONE)
4. **NCCTG-N0745 Phase II/I Trial of Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients with Locally Advanced or Metastatic Liver Cancer (MAYO)**

5. A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma (MAYO)
6. **Chemoembolization with or without Sorafenib Tosylate in Treating Patients with Liver Cancer that cannot be Removed by Surgery (MAYO)**
7. Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for those Subjects who have Failed Sorafenib Treatment (MAYO)

D. Pancreatic Cancer

1. 20082214 Phase III Randomized Study of Weekly ABI-007 plus Gemcitabine vs. Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas (ACC, TGEN)
2. **20100711 Phase III Study of Chemotherapy and Chemoradiotherapy with or without HyperAcute-Pancreatic Cancer Vaccine in Subjects with Surgically Resected Pancreatic Cancer (ACC)**
3. CA046 Phase III Trial of Patients with Metastatic Adenocarcinoma of the Pancreas (MAYO, TGEN)
4. **20101126 Phase II Randomized Cross-Over Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination with Gemcitabine Compared with Gemcitabine Alone in Previously Untreated Patients with Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma (ACC)**
5. J1013 Phase II Study of Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas (TGEN)
6. **MC0547 Phase II Trial using AZD0530 in Treating Patients with Previously Treated Metastatic Pancreatic Cancer (MAYO)**
7. PCYC-1001 Phase II Study of Safety and Tolerability of PCI-27483 in Patients with Pancreatic Cancer Patients Receiving Treatment with Gemcitabine (TGEN)
8. **SU2C-001 Phase II Study of Therapy Selected by Molecular/Metabolic Profiling in Patients with Previously Treated Metastatic Pancreatic Cancer (TGEN)**
9. TH-CR-404 Phase II Study of the Safety and Efficacy of TH-302 in Combination with Gemcitabine Compared with Gemcitabine Alone in Previously Untreated Patients with Pancreatic Adenocarcinoma (MAYO)
10. **Phase II Study of Coagulation Factor VIIA Inhibitor PCI-27483 In Pancreatic Cancer Patients (TGEN)**
11. Stand Up to Cancer: Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination with GDC-0449 (Hedgehog Inhibitor) in Patient with Previously Untreated Metastatic Adenocarcinoma of the Pancreas (TGEN)
12. **Phase I Randomized Phase II Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer (TGEN)**
13. 12096 Phase II/I Study for Patients with Pancreatic Cancer (LILLY)
14. **Phase I Open-Label, Dose Escalation Study of ASG-5ME in Patients with Pancreatic Adenocarcinoma (TGEN)**
15. GDC-0449 and Erlotinib Hydrochloride with or without Gemcitabine Hydrochloride in Treating Patients with Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (MAYO)
16. **Gemcitabine and Erlotinib before and after Surgery in Treating Patients with Pancreatic Cancer that can be Removed by Surgery (MAYO)**
17. Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients with Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (MAYO)

4. Gynecologic Cancers

A. Ovarian / Peritoneal Cancer

1. 10-0475-10, GOG 0252 Phase III Clinical Trial of Bevacizumab with IV vs. IP Chemotherapy in Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: NCI-Supplied Agent: Bevacizumab (NSC #704865, IND #7921) (ACC)
2. **10-0857-10, GOG0262 Randomized Phase III Trial of Every-3-Weeks Paclitaxel vs. Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (Nsc #704865, Ind #7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer (ACC)**
3. 20082147 Phase III Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-Sensitive Ovarian Cancer in First Relapse (ACC)
4. **GOG-0212 Phase III Trial of Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients with Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer (MAYO)**
5. GOG-0252 Phase III Trial using Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients with Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (MAYO, ST. JOSEPH)
6. **MORAb003-004 Phase III Trial using Efficacy and Safety of MORAb-003 in Subjects with Platinum-Sensitive Ovarian Cancer in First Relapse (ST. JOSEPH)**
7. Phase III Taxol/Carboplatin +/- Farletuzumab (AO)
8. **04-0707-04 Phase IIA Prospective Study of the Effect of Flutamide (125 or 250 mg/day) Taken for 6 Weeks on Expression of Potential Biomarkers of Flutamide Action in the Ovaries of Women at Increased Risk for Ovarian Cancer (ACC)**
9. 08-1137-04 Phase II Open Label Trial of Bendamustine HCL in Women With Advanced Ovarian Cancer (ACC)
10. **10-0524-04, S0904 Phase II Randomized Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (ACC)**
11. GOG-0260 Phase II Trial using Elesclomol Sodium and Paclitaxel in Treating Patients with Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (ST. JOSEPH)
12. **MAYO-MC0261 Phase II Trial of Cisplatin and Flavopiridol in Treating Patients with Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer (MAYO)**
13. MORAb003-003PR Phase II Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer (ST. JOSEPH)
14. **07-0638-04 Phase I Open Label Trial of Alimta Plus Cisplatin and Paclitaxel Given Intraperitoneally (IP) as First Line Treatment for Women with Stage III Ovarian Cancer (ACC)**
15. 10-0315-04, GOG 0256 Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment in Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ACC)
16. **Paclitaxel and Carboplatin or Ifosfamide in Treating Patients with Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer (MAYO)**
17. Paclitaxel and Carboplatin with or without Bevacizumab in Treating Patients with Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (MAYO)

18. Virus Therapy in Treating Patients with Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer (MAYO)

B. Uterine / Cervical Cancer

1. 10-0254-10 Phase III Trial of Pelvic Radiation Therapy vs. Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma (ACC)
2. **GOG-0258 Phase III Trial using Carboplatin and Paclitaxel with or without Cisplatin and Radiation Therapy in Treating Patients with Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer (MAYO, ST. JOSEPH)**
3. GOG-0240 Phase III Trial of Paclitaxel and Cisplatin or Topotecan with or without Bevacizumab in Treating Patients with Stage IVB, Recurrent, or Persistent Cervical Cancer (MAYO)
4. **09-1131-04 Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Non Squamous Cell Carcinoma of the Cervix (Abraxis BioScience, LLC Study #CA026, ABX257-GYN08US) (ACC)**
5. 10-0136-04, PROTOCOL GOG-0086P Phase II Three Arm Randomized Study of Paclitaxel/Carboplatin/Bevacizumab (NSC#704865, IND#7921), Paclitaxel/Carboplatin/ Temozolomide (NSC#683864, IND#61010) and Ixabepilone (NSC#710428, IND# 59699)/ Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer (ACC)
6. **HSC05127 Randomized Double-Blind Phase II Trial of Celecoxib, a Cox-2 Inhibitor, in the Treatment of Patients with Cervical Intraepithelial Neoplasia 3 (CIN3) (ACC)**
7. NV25025 Phase II Study of RO5217790 (HPV Targeted Immunotherapy) in Patients with High Grade Cervical Intraepithelial Neoplasia Associated with High Risk HPV Infection (GENE)
8. **2010_515 Phase II/I Study of MK1775 in Combination with Topotecan/Cisplatin in Patients with Cervical Cancer (1775-008) (MERCK)**
9. Chemotherapy and Pelvic Radiation Therapy with or without Additional Chemotherapy in Treating Patients with High-Risk Early-Stage Cervical Cancer after Radical Hysterectomy (MAYO)
10. **Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temozolomide or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients with Stage III, Stage IV, or Recurrent Endometrial Cancer (MAYO)**
11. Radiation Therapy with or without Chemotherapy in Patients with Stage I or Stage II Cervical Cancer who Previously Underwent Surgery (MAYO)

5. Head & Neck Cancer

1. UCCRC-10-428-B Phase II Study of Temozolomide with or without Cetuximab in Patients with Recurrent and/or Metastatic Head and Neck Cancer who did not Respond to Previous Therapy (MAYO) 3'-Deoxy-3'-[18F] Fluorothymidine and Fluorodeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients with Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx (MAYO)
2. **Dose Escalation Study of Hyperbaric Oxygen with Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck (MAYO)**
3. Efficacy Study of REOLYSIN in Combination with Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers (MAYO)
4. **Fluorodeoxyglucose F 18-PET/CT Imaging in Assessing the Tumor and Planning Neck Surgery in Patients with Newly Diagnosed Head and Neck Cancer (MAYO)**

5. Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients with Newly Diagnosed Nasopharyngeal Cancer (MAYO)

6. Lung

1. 09-1104-10, S0819 Phase III Randomized Study Comparing Carboplatin/Paclitaxel or Advanced Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Non-Small Cell Lung Cancer (NSCLC) (ACC)
2. **13852 Phase III Study in Second Line Non Small Cell Lung Cancer (IMCLONE)**
3. 9707 Phase III Study of Pemetrexed, Carboplatin and Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer (LILLY)
4. **11514 Phase III Trial using Chemotherapy and Radiation in Treating Patients with Stage III Non-Small Cell Lung Cancer (LILLY)**
5. 13258 Phase III Study of Patients with Advanced Non-Small Cell Lung Cancer (LILLY)
6. **109493 Phase III Trial using GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Non-Small Cell Lung Cancer (GSK)**
7. CALGB-30610 Phase III Trial using Three Different Radiation Therapy Regimens in Treating Patients with Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide (MAYO)
8. **CTI-PGT-07-00400 Phase III Trial Evaluating Carboplatin with Either Paclitaxel Poliglumex or Paclitaxel in Treating Women with Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (AO)**
9. ECOG-1505 Phase III Trial using Chemotherapy with or without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery (MAYO)
10. **MAGRIT/109493 Phase III Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer (NSCLC) (ACC)**
11. NR001-03 Phase III Lucanix Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (MAYO)
12. **09-0016-04, S0722 Phase II Trial of MTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM) (ACC)**
13. 09-0651-04, S0709 Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/Erlotinib or Erlotinib alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 (Ps 2) Selected by Serum Proteomics (ACC)
14. **09-1047-04, S0720 Phase II ERCC1 AND RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) (ACC)**
15. 09-1105-04, S0802 Phase II Randomized Trial of Weekly Topotecan with and without Ave0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC) (ACC)
16. **10-0647-04, S0636 Phase II Trial of the Combination of Osi-774 (Erlotinib; Nsc-718781) and Bevacizumab (Rhumab Vegf; Nsc-704865) in Never-Smokers with Stage IIIB And IV Primary NSCLC Adenocarcinomas (ACC)**
17. 20100007 Phase II Non-Randomized, Open-Label, Multi-Center, Multi-Cohort Study Evaluating the Efficacy and Safety of STA-9090 in Subjects with Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) (ACC)
18. **ACCL001.0 Phase II Trial using CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Cancer (ST.JOSEPH)**
19. CP12-0917 Phase II Open-Label, Multicenter, Randomized Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-Based Chemotherapy

**CancerPACT is an initiative of Cancer Patients Alliance in Partnership
with Phoenix based Arizona Bridge to Independent Living**

Call (toll free) 1-888-729-0244
www.CancerPACT.org

- vs. Platinum-Based Chemotherapy Alone as First-Line Treatment of Patients with Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC) (ACC)
20. **CBP08-01 Phase II Study of CBP501 + Pemetrexed + Cisplatin in Patients with Malignant Pleural Mesothelioma (MAYO)**
 21. ECOG-E1508 Phase II Trial using Cisplatin and Etoposide Phosphate with or without GDC-0449 or Cixutumumab in Treating Patients with Extensive-Stage Small Cell Lung Cancer (MAYO)
 22. **M10-301 Phase II Study of Carboplatin/Paclitaxel in Combination with ABT-869 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (IRONWOOD, PIVOTAL)**
 23. NCCTG-N0923 Phase II Study using Seneca Valley Virus-001 after Chemotherapy in Treating Patients with Extensive-Stage Small Cell Lung Cancer (MAYO)
 24. **PPHM1001 Phase II Study of Paclitaxel/Carboplatin with or without Baviximab in Previously Untreated Non Small-Cell Lung Cancer (IRONWOOD)**
 25. Phase II Study of REOLYSIN in Combination with Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer with KRAS or EGFR Activation (MAYO)
 26. **20080430 Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients with Advanced Solid Tumors and in Chemotherapy-Naive Patients with Malignant Pleural Mesothelioma (ACC)**
 27. U31287-A-U201 Phase IB/II Randomized, Placebo-Controlled, Double-Blind Study of U3-1287 (AMG 888) in Combination with Erlotinib in EGFR Treatment Naive Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Chemotherapy (ACC, PREMIER)
 28. **Bortezomib, Paclitaxel, and Carboplatin Combined with Radiation Therapy in Treating Patients with Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer that cannot be Removed by Surgery (MAYO)**
 29. Carboplatin and Paclitaxel with or without Bevacizumab and/or Cetuximab in Treating Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (MAYO)
 30. **Gold Sodium Thiomalate in Treating Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (MAYO)**
 31. Stereotactic Body Radiation Therapy in Treating Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) (MAYO)

7. Melanoma / Skin

1. 20081101 Phase III Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy of RecMAGE-A3 + AS15 ASCI as Adjuvant Therapy in Patients with MAGE-A3 Positive Resected Stage III Melanoma (ACC)
2. **20081969 Phase III Randomized Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEX GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients with Unresectable Stage IIIB, IIIC and IV Disease (ACC)**
3. 20082144 Phase III Open Label, Multicenter Trial of ABI-007 vs. Dacarbazine in Previously Untreated Patients with Metastatic Melanoma (ACC)
4. **20092323 BRIM 3: Phase III Randomized, Open-label, Controlled, Multicenter Study in Previously Untreated Patients with Unresectable Stage IIIC or Stage IV Melanoma with V600E BRAF Mutation Receiving RO5185426 or Dacarbazine (ACC)**
5. CA033 Phase III Open-Label, Multicenter Trial of ABI-007 vs. Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma (ACC)
6. **H8K-MC-JZAO Randomized Phase III Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma (ACC)**

**CancerPACT is an initiative of Cancer Patients Alliance in Partnership
with Phoenix based Arizona Bridge to Independent Living**

Call (toll free) 1-888-729-0244
www.CancerPACT.org

7. NCCTG-N0879 Phase II Trial of Carboplatin, Paclitaxel, and Bevacizumab with or without Everolimus in Treating Patients with Metastatic Malignant Melanoma (MAYO)
8. **Phase I Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 Administered Once Weekly for 3 Weeks (days 1, 8, and 15 of a 28-day Cycle) in Subjects with Melanoma (TGEN)**
9. 08-0389-02 Pilot Study of Neurocognitive Function in Patients Treated with Adjuvant Interferon Alpha-2b for High Risk Melanoma (ACC)
10. **10-0574-04 Multicenter Treatment Protocol for Expanded Access Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma (ACC)**
11. Compassionate use Trial for Unresectable Melanoma with Ipilimumab (MAYO)
12. **Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma (MAYO)**
13. Single Arm Open Label Expanded Access Study of GDC-0449 in Patients with Locally Advanced or Metastatic Basal Cell Carcinoma (TGEN)

8. Prostate Cancer

1. 20090335 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer (ACC)
2. **AFFIRM/CRPC2 Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (ACC)**
3. CA184-095 Phase III Study of Immunotherapy to Treat Advanced Prostate Cancer (MAYO)
4. **CC-5013-PC-002 Phase III Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination with Docetaxel and Prednisone for Patients with Castrate-Resistant Prostate Cancer (AO)**
5. ECOG-E3805 Phase III Trial using Androgen Ablation Therapy with or without Chemotherapy in Treating Patients with Metastatic Prostate Cancer (MAYO)
6. **OGX-01-10 Phase III Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as Second Line Therapy in Men with Castrate Resistant Prostate Cancer (CRPC) (MAYO)**
7. PR11 Phase III Trial with Observation or Radical Treatment in Patients with Prostate Cancer (MAYO)
8. **RTOG-0232 Phase III Trial using Interstitial Brachytherapy with or without External-Beam Radiation Therapy in Treating Patients with Prostate Cancer (AOS, MAYO)**
9. RTOG-0534 Phase III Trial using Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy with or without Prostate Radiation Therapy in Treating Patients with a Rising PSA after Surgery for Prostate Cancer (AOS)
10. **RTOG-0815 Phase III Trial of Radiation Therapy with or without Androgen-Deprivation Therapy in Treating Patients with Prostate Cancer (AOS)**
11. Phase III Metastatic First Line Treatment Docetaxel/Prednisone +/- Lenalidomide (AO)
12. **ACCP001.2 Phase II Trial using CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution (ST. JOSEPH)**
13. RTOG-0526 Phase II Trial using Ultrasound-Guided Implant Radiation Therapy in Treating Patients with Locally Recurrent Prostate Cancer Previously Treated with External-Beam Radiation Therapy (AOS)
14. **RTOG-0622 Phase II Trial using Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in**

**CancerPACT is an initiative of Cancer Patients Alliance in Partnership
with Phoenix based Arizona Bridge to Independent Living**

Call (toll free) 1-888-729-0244
www.CancerPACT.org

Treating Patients with Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer (AOS)

15. HE3235-0201 Phase I/II Open-Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3235 when Administered Orally to Patients with Prostate Cancer (ACC)
16. **Bicalutamide and Raloxifene in Treating Patients with Metastatic or Hormone-Refractory Prostate Cancer (MAYO)**
17. Docetaxel and Prednisone with or without Vaccine Therapy in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer (MAYO)
18. **Gene Therapy and Radioactive Iodine in Treating Patients with Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy (MAYO)**
19. Leuprolide Acetate or Goserelin Acetate Compared with Observation in Treating Patients with High-Risk Prostate Cancer who have Undergone Radical Prostatectomy (MAYO)
20. **Study of Immunotherapy to Treat Advanced Prostate Cancer (MAYO)**
21. Surgery with or without Docetaxel and Leuprolide or Goserelin in Treating Patients with High-Risk Localized Prostate Cancer (MAYO)

9. Urologic Cancers (other)

A. Bladder

1. CDX1307-03 Phase II Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) (BCGO)
2. **BC-07-01.CTIL Phase IIB Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer (BCGO)**
3. Longer-term Recurrence Rates in Patients with Bladder Cancer after Hexvix (Cysview) Fluorescence Cystoscopy/TURB (MAYO)

B. Kidney Cancer

1. 10-0176-04, E2804 The BEST Trial: Phase II Randomized Study of VEGF, RAF Kinase, and MTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temozolomide in Advanced Renal Cell Carcinoma (ACC)
2. **20081525 Phase II, Single Arm Study of Pralatrexate in Patients with Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urothelium (ACC)**
3. ECOG-E1808 Phase II Trial Evaluating Sunitinib Malate with or without Gemcitabine Hydrochloride in Treating Patients with Advanced Kidney Cancer that cannot be Removed by Surgery (MAYO)
4. **CVX-060-102 Phase IB/II, Multicenter, Trial of CVX-060, a Selective Angiopoietin-2 (ANG-2) Binding, Anti-Angiogenic Covx-Body, in Combination with Sunitinib in Patients with Advanced Renal Cell Carcinoma (ACC)**
5. Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients with High-Risk Kidney Tumors (MAYO)
6. **Gemcitabine Hydrochloride and Cisplatin with or without Bevacizumab in Treating Patients with Advanced Urinary Tract Cancer (MAYO)**
7. ECOG-E1808 Phase II Trial Evaluating Sunitinib Malate with or without Gemcitabine Hydrochloride in Treating Patients with Advanced Kidney Cancer that cannot be Removed by Surgery (MAYO)

**CancerPACT is an initiative of Cancer Patients Alliance in Partnership
with Phoenix based Arizona Bridge to Independent Living**

Call (toll free) 1-888-729-0244
www.CancerPACT.org

8. **Trial of Maintenance SUO11248 vs. Placebo Post Chemotherapy for Patients with Advanced Urothelial Carcinoma (MAYO)**

10. Endocrine

1. 20090055 Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs. Octreotide LAR in Patients with Metastatic Carcinoid Tumors whose Disease-Related Symptoms are Inadequately Controlled by Somatostatin Analogues (ACC)
2. **OSI-906 GALACCTIC: Phase III Randomized, Double-Blind, Placebo-Controlled Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma (TGEN)**
3. Phase III International, Randomized, Double-Blinded, Efficacy Study of XL184 vs. Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer (TGEN)
4. **114144 Phase II Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors (GSK)**
5. MAYO-8035 Phase II Study of Gossypol Acetic Acid in Treating Patients with Recurrent, Metastatic, or Primary Adrenocortical Cancer that cannot be Removed by Surgery (MAYO)
6. **MC057H Phase II Trial using Pazopanib in Treating Patients With Advanced Thyroid Cancer (MAYO)**
7. XL184-301 Phase III Trial using Efficacy of XL184 in Advanced Medullary Thyroid Cancer (MAYO, TGEN)
8. **CDKO-125a-006 Phase II Study of Oral PHA-848125AC I Patients with Thymic Carcinoma Previously Treated with Chemotherapy (TGEN)**
9. Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients with Rare Tumors of Neuroendocrine Origin (TGEN)
10. **Pazopanib in Treating Patients with Advanced Thyroid Cancer (MAYO)**
11. Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients with Metastatic Carcinoid Disease (MAYO)
12. **Safety and Efficacy of VB-111 in Subjects with Advanced Differentiated Thyroid Cancer (MAYO)**

11. Sarcoma

1. 20081195 Phase I/II Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma (ACC)
2. **Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients with Rhabdomyosarcoma or Other Soft Tissue Sarcoma (MAYO)**
3. Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients with Osteosarcoma (MAYO)
4. **Dose-Escalation Study of TH-302 in Combination with Doxorubicin to Treat Patients with Advanced Soft Tissue Sarcoma (MAYO)**
5. Gemcitabine Hydrochloride and Docetaxel with or without Bevacizumab in Treating Patients with Advanced or Recurrent Uterine Leiomyosarcoma (MAYO)
6. **Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients with Metastatic Rhabdomyosarcoma (MAYO)**

**CancerPACT is an initiative of Cancer Patients Alliance in Partnership
with Phoenix based Arizona Bridge to Independent Living**

Call (toll free) 1-888-729-0244
www.CancerPACT.org

Hematologic Cancers

1. Leukemia

1. CC-5013 Phase III Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients with B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL) (MAYO)
2. **20092127 Phase II Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients with Acute Myeloid Leukemia (AML) with FLT3-ITD Activating Mutations (ACC)**
3. ECOG-E1905 Phase II Trial using Azacitidine with or without MS-275 in Treating Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (MAYO)
4. **ECOG-E1908 Phase II Trial using Rituximab and Alemtuzumab in Treating Older Patients with Progressive Chronic Lymphocytic Leukemia (MAYO)**
5. ECOG-2903 Phase II Trial using Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (MAYO)
6. **GVHD-2007-001 Phase I Safety Study of MultiStem in Patients with Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia (MAYO)**
7. 10-0637-10, COG AALL08B1 Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (ACC)
8. **COG AALL9032 Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) (ACC)**
9. AZD2171 in Treating Patients with Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (MAYO)
10. **Bortezomib and Combination Chemotherapy in Treating Young Patients with Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (MAYO)**
11. Combination Chemotherapy in Treating Young Patients with Newly Diagnosed Acute Promyelocytic Leukemia (MAYO)
12. **Collecting and Storing Samples of Bone Marrow and Blood From Patients with Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma (MAYO)**
13. Comparing Three Different Combination Chemotherapy Regimens in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia (MAYO)
14. **Daunorubicin, Cytarabine, and Midostaurin in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia (MAYO)**
15. Donor Stem Cell Transplant in Treating Young Patients with Acute Myeloid Leukemia with Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia (MAYO)
16. **Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) (MAYO)**
17. Gemtuzumab and Combination Chemotherapy in Treating Patients with Previously Untreated Acute Promyelocytic Leukemia (MAYO)
18. **Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients with High Risk Chronic Lymphocytic Leukemia (MAYO)**
19. Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients with Relapsed B-Cell Acute Lymphoblastic Leukemia (MAYO)
20. **Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAYO)**

**CancerPACT is an initiative of Cancer Patients Alliance in Partnership
with Phoenix based Arizona Bridge to Independent Living**

Call (toll free) 1-888-729-0244
www.CancerPACT.org

21. Panobinostat and Everolimus in Treating Patients with Recurrent Multiple Myeloma, Non- Hodgkin Lymphoma, or Hodgkin Lymphoma (MAYO)
22. **Pentostatin, Alemtuzumab, and Rituximab in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAYO)**
23. Risk-Based Classification System of Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (MAYO)

2. Lymphoma

1. 20092045 Phase III Randomized, Double-Blind, Placebo-Controlled Study of SGN-35 (Brentuximab Vedotin) and Best Supportive Care (BSC) vs. Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma (HL) Following Autologous Stem Cell Transplant (ASCT) (ACC)
2. **CRAD001N2301 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 vs. Matching Placebo after Patients have Achieved Complete Response with First-line Rituximab-Chemotherapy (IRONWOOD, MAYO)**
3. Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study of Panobinostat for Maintenance of Response in Patients with Hodgkin's Lymphoma (MAYO)
4. **05-0303-01 Phase II Trial of Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin's Lymphoma (ACC)**
5. 08-1071-04 Phase II Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas (ACC)
6. **09-0779-04, S0801 Phase II Study of Iodine-131 Labeled Tositumomab in Combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients with Advanced Stage Follicular Non-Hodgkin's Lymphoma (ACC)**
7. 20091887 Phase II Multi-Center, Single-Arm, Open-Label Exploratory Study of Individually-Optimized Conditioning Using Pharmacokinetics [PK]-directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects with Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma (ACC)
8. **CDR0000600003 Phase II Trial using Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma (MAYO)**
9. CDR000061788 Phase II Trial using Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients with Previously Untreated Low-Grade Non-Hodgkin Lymphoma (MAYO)
10. **CDR0000655078 Phase II Trial using Bortezomib, Cladribine, and Rituximab in Treating Patients with Advanced Mantle Cell Lymphoma or Indolent Lymphoma (ST. JOSEPH)**
11. CDR0000630491 Phase II Trial using Pentostatin, Cyclophosphamide, and Rituximab with or without Bevacizumab in Treating Patients with B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAYO)
12. **P276-00/23/08 Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma (MAYO)**
13. MC0983 Phase II Trial of Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAYO)
14. **MC088C Phase II/I Trial using Everolimus and Alemtuzumab in Treating Patients with Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAYO)**

15. MC0886 Phase II/I Trial using Panobinostat and Everolimus in Treating Patients with Recurrent Multiple Myeloma, Non- Hodgkin Lymphoma, or Hodgkin Lymphoma (MAYO)
16. **MC0981 Phase II/I Trial of Everolimus and Lenalidomide in Treating Patients with Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma (MAYO)**
17. 10-0858-04, S0806 Phase I/II Trial of Vorinostat (Saha) (Nsc-701852) in Combination with Rituximab-Chop in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) (ACC)
18. **Phase I Study of Brentuximab Vedotin Combined with ABVD for Hodgkin Lymphoma (MAYO)**
19. 09-0788-04 Retrospective Analysis: The Efficacy of Cladribine in Patients Diagnosed with Mantle Cell Lymphoma (ACC)
20. **20092131 Prospective, Longitudinal, Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma (COMPLETE) (ACC)**
21. A Study to Determine the Efficacy and Safety of Lenalidomide in Patients with Mantle Cell NHL who have Relapsed or Progressed after Treatment with Bortezomib or are Refractory to Bortezomib. The "EMERGE" Trial (MAYO)
22. **Bendamustine Hydrochloride and Rituximab with or without Bortezomib Followed by Rituximab with or without Lenalidomide in Treating Patients with High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma (MAYO)**
23. Bortezomib and Combination Chemotherapy in Treating Young Patients with Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (MAYO)
24. **Collecting and Storing Samples of Bone Marrow and Blood From Patients with Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma (MAYO)**
25. Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients with Complete Remission Following a Bone Marrow Transplant for Hodgkin Lymphoma (MAYO)
26. **Panobinostat in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (MAYO)**
27. Pentostatin, Alemtuzumab, and Rituximab in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAYO)
28. **Study of RAD001 in Patients with Relapsed/Refractory Hodgkin Lymphoma that has Progressed after High-Dose Chemotherapy and Autologous Stem Cell Transplant and/or after Gemcitabine- or Vinorelbine- or Vinblastine-Based Treatment (MAYO)**
29. Two Different Methods of Collecting Stem Cells for an Autologous Stem Cell Transplant in Treating Patients with Diffuse Large Cell Lymphoma (MAYO)
30. **Vaccine Therapy with or without Cryosurgery in Treating Patients with Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma (MAYO)**

3. Myeloma

1. CC-4047-MF-002 Phase III Study of Pomalidomide in Persons with Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence (MAYO)
2. **ECOG-E1A06 Phase III Trial using Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients with Newly Diagnosed Multiple Myeloma (MAYO)**
3. PX-171-009 Phase III Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs. Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma (MAYO)
4. **SWOG-S0777 Phase III Trial of Lenalidomide and Dexamethasone with or without Bortezomib in Treating Patients with Previously Untreated Multiple Myeloma (MAYO)**
5. CDR0000574742 Phase II Trial using CC-4047 and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma or Amyloidosis (MAYO)

**CancerPACT is an initiative of Cancer Patients Alliance in Partnership
with Phoenix based Arizona Bridge to Independent Living**

Call (toll free) 1-888-729-0244
www.CancerPACT.org

6. **ECOG-E2A08 Phase II Trial of Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients with Multiple Myeloma that Relapsed after Autologous Stem Cell Transplant (MAYO)**
7. MAYO-MC0888 Phase II Trial of Dinaciclib in Treating Patients with Relapsed or Refractory Multiple Myeloma (MAYO)
8. **MC0889 Phase II Trial using Plerixafor in Treating Patients with Multiple Myeloma Previously Treated with Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant (MAYO)**
9. ECOG-E2A08 Phase II Trial of Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients with Multiple Myeloma that Relapsed after Autologous Stem Cell Transplant (MAYO)
10. **20100667 Phase IIA Study of Once Daily Intravenous Busulfan with Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects with Relapsed Multiple Myeloma after Prior Autologous HSCT (ACC)**
11. CDR0000617813 Phase II/I Study of Lenalidomide and Low-Dose Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma and Kidney Dysfunction (MAYO)
12. **MC0982 Phase II/I Trial of Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients with Newly Diagnosed Active Multiple Myeloma (MAYO)**
13. CAUY922A2103 Phase I-IB/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination with Bortezomib, with or without Dexamethasone, in Patients with Relapsed or Refractory Multiple Myeloma (MAYO)
14. **PX-171-007 Phase IB/II Study of Carfilzomib in Relapsed Solid Tumors and Multiple Myeloma (PREMIER)**
15. A041-01 Phase I Open-Label, Multiple Dose, Dose Escalation Study of ACE-041 in Patients with Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma (ACC)
16. **MFG4809g Phase I Study of the Safety and Pharmacokinetics of MFGR1877S in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma (MAYO)**
17. 10-0636-04 Trial of Single Autologous Transplant with or without Consolidation Therapy vs. Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma, Version 2.0 (ACC)
18. **Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients with Relapsed or Refractory Multiple Myeloma (MAYO)**
19. Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma (MAYO)
20. **Lenalidomide or Observation in Treating Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (MAYO)**
21. Obatoclox and Bortezomib in Treating Patients with Relapsed or Refractory Multiple Myeloma (MAYO)
22. **Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients with Previously Treated Multiple Myeloma (MAYO)**
23. Sorafenib and Everolimus in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma (MAYO)
24. **Study to Determine Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone vs. Melphalan, Prednisone, Thalidomide in Patients with Previously Untreated Multiple Myeloma (MAYO)**
25. Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral MLN9708 in Adult Patients with Relapsed and Refractory Multiple Myeloma (MAYO)
26. **Vaccine Therapy with or without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma (MAYO)**

Phase I Studies

1. 113486 Phase I Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination with Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, or Nab-Paclitaxel (GSK)
2. **20591 Phase I/II Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination with A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients with Advanced Solid Tumor (ACC)**
3. CL-CPI-613-002 Phase I/II Open Label Clinical Trial to Evaluate CPI-613 in Patients with Advanced Malignancies (PIVOTAL)
4. **CO-2C-001 Phase I Study of GO-203-2C Given Intravenously in Patients with Advanced Solid Tumors (TGEN)**
5. JI-101-001 Phase I/II Multicenter, Open-Label, Dose-Escalation Study of JI-101, an Oral Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors (ACC)
6. **Phase I/II First in Human, Single-arm, Open-Label Study of Once a Day, Orally Administered BMN 673 in Patients with Advanced or Recurrent Solid Tumors (TGEN)**
7. Phase IB/IIA Safety and Pharmacokinetic Study of IT-101 in the Treatment of Advanced Solid Tumors (TGEN)
8. **Phase I/IIA Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin (Yondelis) in Subjects with Advanced Malignancies and Hepatic Dysfunction (TGEN)**
9. PX-171-007 Phase IB/II Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects with Relapsed Solid Tumors (ACC)
10. **05-0108-04 Phase I Dose Escalation Trial of Biweekly Alimta (with Vitamin Supplementation) in Combination with Taxotere in Advanced Solid Tumor Patients (ACC)**
11. 07-0612-04 Phase I Study of Concomitant Pemetrexed and CDDP Plus Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal (GEJ) Carcinomas (ACC)
12. **105ST101 Phase I Open Label Dose Finding Study of TRC105 In Patients with Advanced or Metastatic Solid Cancer In Whom Curative Therapy is Unavailable (ACC)**
13. 20050693 Phase I Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects with Advanced Malignant Solid Tumors (ACC)
14. **20070282 Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients with Advanced or Metastatic Tumors (ACC)**
15. 2009-003 Phase I Open-label, Dose Escalation Study of ONX 0912 Administered Orally in Patients with Advanced Refractory or Recurrent Solid Tumors (ACC)
16. **20100494 Phase I Open-Label Dose Escalation Study of AT13387 in Patients with Metastatic Solid Tumors (ACC)**
17. CVX-241-101 Phase I Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CVX-241, a Selective Angiopoietin-2 and Vascular Endothelial Growth Factor Binding, Anti-Angiogenic Covx-Body, in Patients With Advanced Solid Tumors (ACC)
18. **I4N-MC-CXBA Phase I Study of LY2624587 in Patients with Advanced Cancer (ACC)**
19. INK128-001 Phase I Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects with Advanced Solid Malignancies Followed by an Expansion in Subjects with Measurable Disease (ACC)
20. **IPI493 Phase I Dose Escalation Study of the Safety and Pharmacokinetics of IPI 493 Orally Administered to Patients with Advanced Solid Tumors or Hematologic Malignancies (ACC)**
21. M10-977 Phase I Trial Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor (TGEN)
22. **MEF4693G Phase I Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEGF0444A, Administered Intravenously to Patients with Advanced Solid Tumors (ACC)**

**CancerPACT is an initiative of Cancer Patients Alliance in Partnership
with Phoenix based Arizona Bridge to Independent Living**

Call (toll free) 1-888-729-0244
www.CancerPACT.org

23. MK-4827-011 Phase I Study Evaluating MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) (MERCK)
24. **POA20234 Phase I Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Interrupted Schedule in Patients with Advanced Cancer (ACC)**
25. TKM-PLK1-001 Phase I Dose Escalation Study to Determine Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 (SH)
26. **Phase I Dose Escalation Study of ARQ 621 in Adult Patients with Metastatic Solid Tumors (TGEN)**
27. Phase I Dose-Escalation Study of LY2495655, an Anti-Myostatin Monoclonal Antibody, In Patients with Advanced Cancer (TGEN)
28. **Phase I Dose-Escalation Study of LY2940680 in patients with Advanced Cancer (TGEN)**
29. Phase I Dose Escalation Study of NKP-1339 in Patients with Advanced Solid Tumors Refractory to Treatment (TGEN)
30. **Phase I Dose Escalation Study of NMS-1286937 Administered to Adult Patients with Advanced/Metastatic Solid Tumors (TGEN)**
31. Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM-080301 in Patients with Advanced Solid Tumors (TGEN)
32. **Phase 1 Dose-Escalation Trial of SGN-75 in CD70-Positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma (MAYO)**
33. Phase I Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 out of 4 Weeks in Subject with Advanced Solid Tumors (TGEN)
34. **Phase I Open-Label, Dose-Escalation Study of PI3 Kinase Inhibitor (GDC-0941) in Patients with Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does not Exist or Has Proven Ineffective or Intolerable (TGEN)**
35. Phase I Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients with Advanced Solid Tumor (TGEN)
36. **Phase I Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) with Initial Dexamethasone Premedication Given Intravenously to Patients with Advanced Solid Tumors (TGEN)**
37. Phase I Open Labeled Dose Escalation Study of VELIPARIB in Combination with FOLFIRI in Subjects with Advanced Solid Tumors (TGEN)
38. **Phase I Open-Label, Dose-Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given in a 4-Week on / 2-Week off Schedule in Subjects with Advanced Malignancies (TGEN)**
39. Phase I Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects with BRAF Mutation Positive Tumor (GSK)
40. **Phase I Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects with Advanced Solid Tumors (TGEN)**
41. Phase I Multi-Center, Open Label Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 in Patients with Advanced Solid Tumors with Liver Involvement (TGEN)
42. **Phase I Open Label Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response after Intravenous Administration of Weekly BAY 80-6946 to Patients with Advanced Cancer (TGEN)**

43. Phase I Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of HBI-8000 in Patients with Advanced Solid Tumors or Relapsed or Refractory Lymphoma (TGEN)
44. **Phase I Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genx-644282 in Patients with Advanced Malignant Solid Tumors (TGEN)**
45. Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014, Given by IV Infusion to Patients with Advanced or Metastatic Cancer (TGEN)
46. **Phase I Study of AR-12 in Adult Patients with Advanced or Recurrent Solid Tumors or Lymphoma, for Which No standard Therapy is Available (TGEN)**
47. Phase I Study of BMS-833923 (XL139) in Subjects with Advanced or Metastatic Cancer (MAYO)
48. **Phase I Study of CBP501 + Pemetrexed + Cisplatin in Patients with Solid Tumors (MAYO)**
49. Phase I Study of IPI-926 in Patients with Advanced and/or Metastatic Solid Tumor Malignancies (TGEN)
50. **Phase I Study of NKTR-102 (PEG-Irinotecan) in Combination with 5-Fluorouracil and Leucovorin (FULPIRI) in Patients with Advanced Cancer (TGEN)**
51. Phase I Study of Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors (MAYO)
52. **Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients with Advanced Solid Tumors (TGEN)**
53. Phase I Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumor or Hematologic Malignancies in which the Target Kinases are linked to Disease Pathophysiology (TGEN)
54. **Phase I Study using Everolimus and Gemcitabine Hydrochloride in Treating Patients with Unresectable Solid Tumors Refractory to Standard Therapy (MAYO)**
55. Phase I Trial of Cilengitide and Paclitaxel in Treating Patients with Advanced Solid Tumors (MAYO)
56. **Phase I Trial using Dasatinib and Lapatinib in Treating Patients with Advanced Solid Tumors that cannot be Removed by Surgery (MAYO)**
57. Phase I Trial using Vatalanib and Pemetrexed Disodium in Treating Patients with Advanced Solid Tumors (MAYO)
58. **MEK113486 Phase I/IB Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination with Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, or nab-Paclitaxel in Subjects with Advanced Solid Tumors (ACC)**
59. 20081777 Phase IB Open-Label, Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination with other Anticancer Treatment in Patients with Solid Tumors (ACC)
60. **EGF111767 Phase IB Open-Label Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination with other Anticancer Treatment in Patients with Solid Tumors (ACC)**
61. H8K-MC-JZAN Phase IB Multicenter, Dose-Escalation Study of LY573636 in Combination with Liposomal Doxorubicin in Patients with Advanced Solid Tumors (ACC, LILLY)
62. **MEF4797G Phase IB Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MEGF0444A, A Humanized IgG1 Antibody, in Combination With Bevacizumab with or without Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors (ACC)**
63. ORA-09-001 Phase IB Trial of Lenalidomide (Revlimid®) with Erlotinib (Tarceva) with or without Gemcitabine in Subjects with Advanced Solid Tumors (ACC)
64. **Phase IB Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination with Capecitabine (Xeloda) in Subjects with Advanced Solid Tumors (TGEN)**
65. AMG386 Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 with AMG 706, AMG 386 with Bevacizumab, AMG 386 with Sorafenib, and AMG 386 with Sunitinib in Adult Patients with Advanced Solid Tumors (ACC)
66. **MEK111054 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects with Solid Tumors or Lymphoma (ACC)**
67. AFP464 in Treating Patients with Advanced Solid Tumors (MAYO)

68. **Cixutumumab in Treating Patients with Relapsed or Refractory Solid Tumors (MAYO)**

Other

1. CALGB-70604 Phase III Trial using Zoledronic Acid in Treating Patients with Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma with Bone Involvement (MAYO)
2. **Phase III Open-label Study of Nilotinib vs. Imatinib in GIST Patients (MAYO)**
3. 10-0577-04, S0941 Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC- 718781) in Patients with Advanced Gallbladder Carcinoma or Cholangiocarcinoma (ACC)
4. **MAYO-MC0845 Phase II Trial of Temsirolimus and Bevacizumab in Treating Patients with Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor (MAYO)**
5. XL184-203 Phase II Study of XL184 in Adults with Advanced Malignancies (PREMIER)
6. **Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients with Cholangiocarcinoma of the Gallbladder or Bile Duct (MAYO)**
7. Carboplatin, Paclitaxel, and Everolimus in Treating Patients with Previously Untreated Cancer of Unknown Primary (MAYO)
8. **Dose-Ranging Study of Telintra Tablets + Revlimid in Patients with Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (MAYO)**
9. Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) (MAYO)
10. **Study of CS-1008 in Combination with FOLFIRI in Patients who have Failed Other Treatments (MAYO)**